| Title |
Prognostic Value of BRAFV600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes
|
|---|---|
| Published in |
Annals of Surgical Oncology, July 2012
|
| DOI | 10.1245/s10434-012-2457-5 |
| Pubmed ID | |
| Authors |
Stéphanie Moreau, Philippe Saiag, Philippe Aegerter, Daphné Bosset, Christine Longvert, Zofia Hélias-Rodzewicz, Cristi Marin, Frédérique Peschaud, Sophie Chagnon, Utte Zimmermann, Thierry Clerici, Jean-François Emile |
| Abstract |
BRAF (V600) mutations are frequent in melanomas, and BRAF(V600)-targeted therapy have dramatic, but often transitory, efficacy in stage IV patients. Prognosis of patients with American Joint Committee on Cancer (AJCC) stage III melanoma is heterogeneous. We aimed to determine the overall survival (OS) of stage III patients with a nodal deposit of ≥2 mm according to BRAF (V600) mutations and other previously reported prognostic criteria. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 54 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 18% |
| Student > Ph. D. Student | 8 | 15% |
| Student > Master | 5 | 9% |
| Other | 4 | 7% |
| Professor | 4 | 7% |
| Other | 9 | 16% |
| Unknown | 15 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 40% |
| Biochemistry, Genetics and Molecular Biology | 4 | 7% |
| Agricultural and Biological Sciences | 4 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Business, Management and Accounting | 1 | 2% |
| Other | 4 | 7% |
| Unknown | 17 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2021.
All research outputs
#4,552,623
of 22,953,506 outputs
Outputs from Annals of Surgical Oncology
#1,438
of 6,516 outputs
Outputs of similar age
#31,285
of 165,074 outputs
Outputs of similar age from Annals of Surgical Oncology
#8
of 64 outputs
Altmetric has tracked 22,953,506 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,516 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 165,074 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.